Document is current
Any future updates will be listed below
-
Authors
Matsukawa, Manami
Tomozawa, Chikako
Nakamura, Yoshiaki
Fujisawa, Takao
Kimura, Kaori
Hiraoka, Yumie
Yamashita, Riu
Kosugi, Shinji
Sakurai, Akihiro
Imoto, Issei
Nishigaki, Masakazu
Hirata, Makoto
Kuwata, Takeshi https://orcid.org/0000-0003-0044-953X
Yoshino, Takayuki
-
Funding
Funding for this research was provided by:
National Cancer Center Research and Development Fund (2022-A-07)
- License Information
-
More Information
Article History
Received: 8 January 2025
Accepted: 13 March 2025
First Online: 4 April 2025
Declarations
:
: TY reports honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical, Merck Biopharma, Bayer Yakuhin, Ono Pharmaceutical, MSD K. K., and Sumitomo Corp. TY received research funding from Amgen, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, FALCO Biosystems, Genomedia, Medical and Biological Laboratories, Merus N.V., Molecular Health GmbH, MSD, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics, Sanofi, Sysmex, Taiho Pharmaceutical, and Takeda Pharmaceutical Co., Ltd.. TF received lecture fees from Amelieff and AstraZeneca. The other authors declare that they have no conflicts of interest.
: All patients provided written informed consent prior to the study.
